Eisai Co., Ltd. (ESALF)
OTCMKTS · Delayed Price · Currency is USD
26.76
-1.74 (-6.11%)
At close: Jan 26, 2026
Eisai Revenue
Eisai had revenue of 219.94B JPY in the quarter ending December 31, 2025, with 1.76% growth. This brings the company's revenue in the last twelve months to 808.19B, up 2.09% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
808.19B JPY
Revenue Growth
+2.09%
P/S Ratio
1.72
Revenue / Employee
74.03M JPY
Employees
10,917
Market Cap
8.84B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Eisai News
- 5 days ago - Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - Benzinga
- 6 days ago - Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships - South China Morning Post
- 6 days ago - Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - PRNewsWire
- 7 days ago - Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters
- 17 days ago - FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease - Nasdaq
- 17 days ago - FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector - Nasdaq
- 17 days ago - FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 17 days ago - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga